Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 38
Filtrar
Más filtros










Intervalo de año de publicación
1.
Brain Behav Immun ; 117: 135-148, 2024 03.
Artículo en Inglés | MEDLINE | ID: mdl-38211636

RESUMEN

The mammalian hippocampus can generate new neurons throughout life. Known as adult hippocampal neurogenesis (AHN), this process participates in learning, memory, mood regulation, and forgetting. The continuous incorporation of new neurons enhances the plasticity of the hippocampus and contributes to the cognitive reserve in aged individuals. However, the integrity of AHN is targeted by numerous pathological conditions, including neurodegenerative diseases and sustained inflammation. In this regard, the latter causes cognitive decline, mood alterations, and multiple AHN impairments. In fact, the systemic administration of Lipopolysaccharide (LPS) from E. coli to mice (a model of sepsis) triggers depression-like behavior, impairs pattern separation, and decreases the survival, maturation, and synaptic integration of adult-born hippocampal dentate granule cells. Here we tested the capacity of the macrolide antibiotic azithromycin to neutralize the deleterious consequences of LPS administration in female C57BL6J mice. This antibiotic exerted potent neuroprotective effects. It reversed the increased immobility time during the Porsolt test, hippocampal secretion of pro-inflammatory cytokines, and AHN impairments. Moreover, azithromycin promoted the synaptic integration of adult-born neurons and functionally remodeled the gut microbiome. Therefore, our data point to azithromycin as a clinically relevant drug with the putative capacity to ameliorate the negative consequences of chronic inflammation by modulating AHN and hippocampal-related behaviors.


Asunto(s)
Azitromicina , Sepsis , Femenino , Ratones , Animales , Azitromicina/farmacología , Lipopolisacáridos/farmacología , Escherichia coli , Hipocampo/patología , Neurogénesis/fisiología , Antibacterianos/farmacología , Inflamación/patología , Mamíferos
2.
J Glob Antimicrob Resist ; 22: 462-465, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32348904

RESUMEN

OBJECTIVES: Linezolid is one of the last resort antibiotics effectively used in the treatment of infections caused by multidrug-resistant Gram-positive bacteria. Recent outbreaks of Linezolid resistance have been the great concern worldwide, while many countries have not experienced it. In this work, we aimed to evaluate the existence of linezolid resistance and further clarify potential resistance mechanism(s) in staphylococcal isolates obtained from the hospital in Vietnam, a country in which linezolid resistance had not been previously detected. METHODS: Seventy staphylococcal clinical isolates including MRSA (n=63) and methicillin-resistant coagulase-negative staphylococci (MRCNS, n=7) were collected and analyzed for linezolid resistance. Linezolid-resistant isolates were submitted for whole genome sequencing to search for the resistance determinants. RESULTS: We identified two coagulase-negative staphylococcal isolates that were resistant to linezolid. Whole genome sequencing revealed several alterations in the 23S rRNA and L3, L17, L22, L24, L30 ribosomal proteins. Importantly, both isolates harbour the chloramphenicol/florfenicol resistance (cfr) gene on a plasmid. The plasmid was closely identical to the pLRSA417 plasmid that was originally reported in China. CONCLUSIONS: To the best of our knowledge, this is the first report of cfr-mediated linezolid resistance in clinically isolated staphylococci in Vietnam. We suggest that adequate surveillance is necessary to monitor the dissemination of linezolid resistance among staphylococcal species and other important pathogens.


Asunto(s)
Infecciones Estafilocócicas , Staphylococcus , Proteínas Bacterianas/genética , China , Humanos , Linezolid/farmacología , Pruebas de Sensibilidad Microbiana , Plásmidos/genética , Staphylococcus/genética , Tianfenicol/análogos & derivados , Vietnam
3.
Nat Med ; 25(4): 554-560, 2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-30911133

RESUMEN

The hippocampus is one of the most affected areas in Alzheimer's disease (AD)1. Moreover, this structure hosts one of the most unique phenomena of the adult mammalian brain, namely, the addition of new neurons throughout life2. This process, called adult hippocampal neurogenesis (AHN), confers an unparalleled degree of plasticity to the entire hippocampal circuitry3,4. Nonetheless, direct evidence of AHN in humans has remained elusive. Thus, determining whether new neurons are continuously incorporated into the human dentate gyrus (DG) during physiological and pathological aging is a crucial question with outstanding therapeutic potential. By combining human brain samples obtained under tightly controlled conditions and state-of-the-art tissue processing methods, we identified thousands of immature neurons in the DG of neurologically healthy human subjects up to the ninth decade of life. These neurons exhibited variable degrees of maturation along differentiation stages of AHN. In sharp contrast, the number and maturation of these neurons progressively declined as AD advanced. These results demonstrate the persistence of AHN during both physiological and pathological aging in humans and provide evidence for impaired neurogenesis as a potentially relevant mechanism underlying memory deficits in AD that might be amenable to novel therapeutic strategies.


Asunto(s)
Enfermedad de Alzheimer/patología , Hipocampo/patología , Neurogénesis , Adulto , Biomarcadores/metabolismo , Diferenciación Celular , Giro Dentado/patología , Proteínas de Dominio Doblecortina , Humanos , Proteínas Asociadas a Microtúbulos/metabolismo , Neuropéptidos/metabolismo
4.
J Vis Exp ; (121)2017 03 10.
Artículo en Inglés | MEDLINE | ID: mdl-28362383

RESUMEN

One important feature of the major opportunistic human pathogen Staphylococcus aureus is its extraordinary ability to rapidly acquire resistance to antibiotics. Genomic studies reveal that S. aureus carries many virulence and resistance genes located in mobile genetic elements, suggesting that horizontal gene transfer (HGT) plays a critical role in S. aureus evolution. However, a full and detailed description of the methodology used to study HGT in S. aureus is still lacking, especially regarding natural transformation, which has been recently reported in this bacterium. This work describes three protocols that are useful for the in vitro investigation of HGT in S. aureus: conjugation, phage transduction, and natural transformation. To this aim, the cfr gene (chloramphenicol/florfenicol resistance), which confers the Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A (PhLOPSA)-resistance phenotype, was used. Understanding the mechanisms through which S. aureus transfers genetic materials to other strains is essential to comprehending the rapid acquisition of resistance and helps to clarify the modes of dissemination reported in surveillance programs or to further predict the spreading mode in the future.


Asunto(s)
Proteínas Bacterianas/genética , Farmacorresistencia Bacteriana/genética , Transferencia de Gen Horizontal , Técnicas Genéticas , Staphylococcus aureus/genética , Antibacterianos/farmacología , Conjugación Genética/genética , Farmacorresistencia Bacteriana/efectos de los fármacos , Humanos , Fagos de Staphylococcus/genética , Staphylococcus aureus/efectos de los fármacos , Tianfenicol/análogos & derivados , Tianfenicol/farmacología , Transducción Genética
5.
J Antimicrob Chemother ; 71(3): 587-92, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-26661395

RESUMEN

OBJECTIVES: Linezolid resistance mediated by the cfr gene represents a global concern due to its dissemination among multiresistant nosocomial pathogens such as MRSA and Enterococcus. In the present work, we have evaluated the in vitro transmission of cfr pSCFS7-like plasmids from two Staphylococcus epidermidis ST2 strains (SE45 and SE50) isolated in Spanish hospitals, to clinical MRSA and Enterococcus spp. isolates obtained in Japan, a country in which cfr has not been detected yet. We have also investigated alternative mechanisms of horizontal gene transfer involved in the spread of the cfr gene. METHODS: MRSA (n = 16) and Enterococcus spp. (n = 8) clinical isolates were used as recipients in conjugative experiments. Bacteriophage-mediated transmission was tested using MR83a phage and N315, COL and Mu50 strains. A transformation assay was carried out using a natural competent strain derived from N315. RESULTS: The SE45 strain was able to transfer the cfr gene to all strains tested, while transmission from SE50 was observed only to a few strains and with less efficiency. No transmission was observed to Enterococcus spp. isolates. Even though conjugation is thought to be the main mechanism of cfr dissemination, we have demonstrated that transduction can be considered an alternative pathway for transmission of the cfr gene between MRSA strains. However, the results suggest an absence of transmission by natural transformation. CONCLUSIONS: Linezolid resistance mediated by cfr vectors, such as pSCFS7-like plasmids, can be efficiently transferred to clinical MRSA in Japanese isolates. After reaching the staphylococcal pool, the cfr gene could be spread among MRSA strains by either conjugation or transduction.


Asunto(s)
Antibacterianos/farmacología , Farmacorresistencia Bacteriana , Enterococcus/genética , Transferencia de Gen Horizontal , Linezolid/farmacología , Staphylococcus aureus Resistente a Meticilina/genética , Staphylococcus epidermidis/genética , Bacteriófagos , Conjugación Genética , Enterococcus/efectos de los fármacos , Genes Bacterianos , Humanos , Japón , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Plásmidos , España , Staphylococcus epidermidis/efectos de los fármacos , Transducción Genética , Transformación Bacteriana
6.
Rev. esp. quimioter ; 28(2): 101-108, abr. 2015. ilus, tab, graf
Artículo en Inglés | IBECS | ID: ibc-136277

RESUMEN

Objectives. The main objective of the present study is to analyze different genotypic and phenotypic traits related to virulence in Enterococcus faecalis, as well as evaluated the agar invasion phenotype in a collection of isolates with different clinical origins. Material and methods. Seventy-nine E. faecalis isolates, with invasive and non-invasive clinical origins, have been used in this work. Presence of cytolysin activator (cylA), gelatinase (gelE), surface protein (esp), aggregation substance (asa1), endocarditis antigen (efaA), and collagen-binding protein (ace) have been analyzed by PCR. Phenotypic characterization included gelatinase activity, haemolysin production, biofilm formation and agar invasion. Results. All the isolates tested harboured at least one of the virulence determinants. The 95.5% of isolates from haematologic samples were positive for agar invasion test, significantly higher than isolates from non-invasive diseases. A significant reduction in relative invasion area was observed in three selected agar-invasive strains after 15 serial passages. Conclusions. It has been observed a significant high prevalence of agar-invasion positive isolates among strains belonged to haematological samples. Agar invasiveness is reduced after adaptation of clinical isolates to laboratory conditions, showing that agar invasion phenotype can be modulate by culture conditions as other virulence factors observed in different bacterial species (AU)


Objetivos. El principal objetivo de este trabajo es la caracterización de determinantes de virulencia genotípicos y fenotípicos relacionados con patogenicidad en Enterococcus faecalis, evaluando además el fenotipo de invasión en agar en una colección de aislados clínicos de diversa procedencia. Material y métodos. Se han analizado 79 cepas de E. faecalis aisladas en infecciones invasivas y no invasivas. La detección de los principales determinantes asociados a la virulencia (cylA, gelE, esp, asa1, efaA y ace) se ha realizado mediante PCR. La caracterización fenotípica incluyó la detección de actividad gelatinasa, hemólisis, formación de biofilm y el test de invasión en agar. Resultados. Todos los aislados presentaron, al menos, un determinante de virulencia. El 95,5% de las cepas provenientes de hemocultivos resultaron positivas para el test de invasión en agar, significativamente superior a lo observado en cepas de origen clínico no invasivo. En tres cepas seleccionadas, positivas para el test de invasión en agar, se observó una reducción significativa del área relativa de invasión tras 15 pases seriados. Conclusiones. Se ha observado una alta prevalencia de cepas con alto grado de invasión en agar en los aislados hematológicos. Dicho grado de invasión disminuye significativamente al adaptar tres cepas al crecimiento en condiciones de laboratorio, sugiriendo una modulación en función de las condiciones de cultivo tal y como ocurre con otros determinantes asociados a virulencia en diferentes especies bacterianas (AU)


Asunto(s)
Humanos , Enterococcus faecalis/patogenicidad , Recuento de Colonia Microbiana/métodos , Agar , Técnicas de Genotipaje/métodos , Fenotipo , Infecciones por Bacterias Grampositivas , Biopelículas/crecimiento & desarrollo
7.
Sci Rep ; 4: 5440, 2014 Jun 25.
Artículo en Inglés | MEDLINE | ID: mdl-24961911

RESUMEN

In the attempt to find valid alternatives to classic antibiotics and in view of current limitations in the efficacy of antimicrobial-coated or loaded biomaterials, this work is focused on the development of a new glass-ceramic with antibacterial performance together with safe biocompatibility. This bactericidal glass-ceramic composed of combeite and nepheline crystals in a residual glassy matrix has been obtained using an antimicrobial soda-lime glass as a precursor. Its inhibitory effects on bacterial growth and biofilm formation were proved against five biofilm-producing reference strains. The biocompatibility tests by using mesenchymal stem cells derived from human bone indicate an excellent biocompatibility.


Asunto(s)
Antibacterianos/farmacología , Cerámica/farmacología , Materiales Biocompatibles Revestidos/farmacología , Viabilidad Microbiana/efectos de los fármacos , Compuestos de Aluminio/química , Antibacterianos/química , Apoptosis/efectos de los fármacos , Biopelículas/efectos de los fármacos , Biopelículas/crecimiento & desarrollo , Compuestos de Calcio/química , Caspasa 3/metabolismo , Adhesión Celular/efectos de los fármacos , Células Cultivadas , Cerámica/química , Materiales Biocompatibles Revestidos/química , Activación Enzimática/efectos de los fármacos , Escherichia coli/efectos de los fármacos , Escherichia coli/fisiología , Humanos , Células Madre Mesenquimatosas/efectos de los fármacos , Células Madre Mesenquimatosas/enzimología , Microscopía Electrónica de Rastreo , Microscopía Electrónica de Transmisión , Óxidos/química , Silicatos/química , Compuestos de Sodio/química , Hidróxido de Sodio/química , Propiedades de Superficie , Termografía , Factores de Tiempo , Difracción de Rayos X
8.
Rev Esp Quimioter ; 26(3): 220-5, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24080888

RESUMEN

INTRODUCTION: This study explores effects of pH and inoculum size on imipenem versus tigecycline activity against E. coli, B. fragilis and E. faecalis, both in individual and mixed cultures. METHODS: MIC/MBCs (mg/L) of tigecycline and imipenem were 0.12/≥ 16 and 4/4 for E. coli, 0.12/0.5 and ≥ 16/≥ 16 for B. fragilis, and 0.12/≥ 16 and 2/≥ 16 for E. faecalis, respectively. Killing curves in supplemented Brucella broth were performed at pH 7 or 5.8, with two final inocula (≈ 105 or ≈ 107 cfu/ml) of each isolate (individual cultures) and with 1:1:1 mixed inocula. Tubes were 48 h incubated at 37 ºC in anaerobiosis. Final concentrations (estimated concentrations in colon) were 1.50 mg/L for tigecycline and 26.40 mg/L for imipenem, with antibiotic-free curves as controls. Experiments were performed in triplicate. RESULTS: Imipenem showed inoculum effect against E.coli and B. fragilis, with reductions in initial inocula in experiments with standard inocula contrasting with increases in experiments with high inocula (both individual and mixed cultures). Against E. faecalis no inoculum effect for imipenem was observed in individual cultures, with marked reductions in initial inocula regardless inoculum size. However in mixed experiments the indirect protection of E. faecalis by the two gramnegatives resulted in bacterial regrowth. This protection was inoculum-dependant since it occurred with high but not with standard inocula. Tigecycline reduced initial inocula of the three isolates regardless culture type (individual/mixed) or experimental conditions (pH/inocula size), with lower reductions for the tolerant E. faecalis. CONCLUSION: Carbapenemase activity was inoculum-dependant for self-protection and indirect protection of E. faecalis.


Asunto(s)
Antibacterianos/farmacología , Proteínas Bacterianas/metabolismo , Bacteroides fragilis/efectos de los fármacos , Bacteroides fragilis/enzimología , Enterococcus faecalis/efectos de los fármacos , Escherichia coli/efectos de los fármacos , Escherichia coli/enzimología , beta-Lactamasas/metabolismo , Área Bajo la Curva , Carga Bacteriana , Técnicas Bacteriológicas , Medios de Cultivo , Concentración de Iones de Hidrógeno , Imipenem/farmacología , Pruebas de Sensibilidad Microbiana , Minociclina/análogos & derivados , Minociclina/farmacología , Tigeciclina
9.
Rev. esp. quimioter ; 26(3): 220-225, sept. 2013.
Artículo en Inglés | IBECS | ID: ibc-115565

RESUMEN

Introducción. Este estudio explora los efectos del tamaño del inóculo y el pH en la actividad de imipenem versus tigeciclina frente a E. coli, B. fragilis y E. faecalis, en cultivo individual y mixto. Métodos. Los valores de CMI/CMB (mg/L) de tigeciclina e imipenem fueron 0,12/>=16 y 4/4 para E. coli, 0,12/0,5 y >=16/>=16 para B. fragilis, y 0,12/>=16 y 2/>=16 para E. faecalis, respectivamente. Se realizaron curvas de letalidad en caldo Brucella suplementado a pH 7 o 5,8 con dos inóculos finales (≈105 o ≈107 ufc/ml) de cada aislado (cultivos individuales) y de un inóculo mixto en proporción 1:1:1. Los tubos se incubaron durante 48h a 37ºC en anaerobiosis. Las concentraciones antibióticas finales (concentraciones estimadas en colon) fueron 1,50 mg/L de tigeciclina y 26,40 mg/L de imipenem. Se usaron como control curvas de crecimiento bacteriano en medio sin antibiótico y los experimentos se realizaron por triplicado. Resultados. Imipenem mostró efecto inóculo frente a E.coli y B. fragilis, con reducciones del inóculo inicial en los experimentos realizados con inóculo estándar en contraposición a los crecimientos del inóculo inicial observados en los experimentos realizados con inóculo alto, tanto en cultivos individuales como mixtos. Frente a E. faecalis imipenem no presentó efecto inóculo en cultivos individuales, con marcadas reducciones del inóculo inicial con independencia del tamaño del mismo. Sin embargo en cultivo mixto la protección indirecta de E. faecalis por los dos aislados gramnegativos produjo un recrecimiento bacteriano. Esta protección fue dependiente del tamaño del inóculo ya que ocurrió en los experimentos con inóculo alto pero no en los realizados con inóculo estándar. Tigeciclina redujo el inóculo inicial de los tres aislados con independencia del tipo de cultivo (individual/mixto) o las condiciones experimentales (pH/tamaño del inóculo), con menores reducciones en el caso de E. faecalis tolerante a este antibiótico. Conclusión: La actividad carbapenemasa fue inóculo independiente para autoprotección y protección indirecta de E. faecalis (AU)


Introduction. This study explores effects of pH and inoculum size on imipenem versus tigecycline activity against E. coli, B. fragilis and E. faecalis, both in individual and mixed cultures. Methods. MIC/MBCs (mg/L) of tigecycline and imipenem were 0.12/>=16 and 4/4 for E. coli, 0.12/0.5 and >=16/>=16 for B. fragilis, and 0.12/>=16 and 2/>=16 for E. faecalis, respectively. Killing curves in supplemented Brucella broth were performed at pH 7 or 5.8, with two final inocula (≈105 or ≈107 cfu/ml) of each isolate (individual cultures) and with 1:1:1 mixed inocula. Tubes were 48h incubated at 37ºC in anaerobiosis. Final concentrations (estimated concentrations in colon) were 1.50 mg/L for tigecycline and 26.40 mg/L for imipenem, with antibiotic-free curves as controls. Experiments were performed in triplicate. Results. Imipenem showed inoculum effect against E.coli and B. fragilis, with reductions in initial inocula in experiments with standard inocula contrasting with increases in experiments with high inocula (both individual and mixed cultures). Against E. faecalis no inoculum effect for imipenem was observed in individual cultures, with marked reductions in initial inocula regardless inoculum size. However in mixed experiments the indirect protection of E. faecalis by the two gramnegatives resulted in bacterial regrowth. This protection was inoculum-dependant since it occurred with high but not with standard inocula. Tigecycline reduced initial inocula of the three isolates regardless culture type (individual/mixed) or experimental conditions (pH/inocula size), with lower reductions for the tolerant E. faecalis. Conclusion. Carbapenemase activity was inoculum-dependant for self-protection and indirect protection of E. faecalis (AU)


Asunto(s)
Enterococcus faecalis/citología , Enterococcus faecalis , Enterococcus faecalis/aislamiento & purificación , Bacteroides fragilis/citología , Bacteroides fragilis/aislamiento & purificación , Imipenem/análogos & derivados , Imipenem/aislamiento & purificación , Imipenem/metabolismo , Enterococcus faecalis/inmunología , Enterococcus faecalis/metabolismo , Enterococcus faecalis/patogenicidad , Bacteroides fragilis/inmunología , Bacteroides fragilis/patogenicidad , Colifagos/metabolismo , Escherichia coli/inmunología , Escherichia coli/aislamiento & purificación
10.
Rev Esp Quimioter ; 26(2): 97-102, 2013 Jun.
Artículo en Español | MEDLINE | ID: mdl-23817645

RESUMEN

The aim of the study was to investigate biofilm formation in Gram negative bacteria and to quantify biofilm production applying a new developed technique that made possible to compare results about biofilm formation within the different Gram negative bacteria species. A total of 153 Gram negative strains corresponding to 12 different bacterium species were studied applying a variation of the optic density measurement technique reported by Stepanovic et al. Data obtained with optic density analysis allow to classify microorganisms in strong biofilm developers, moderate biofilm developers, weak biofilm developers and no biofilm developers. The results were expressed in two ways, using in both cases the same statistical method: without standardization, where controls were different depending on the day optic density measurements were performed, and standardized using a correction factor, using the same control for every strain of all our bacterium species in our study, which allows result homogenization. The obtained results in our study after data analysis and standardization show that over the 153 Gram negative strains in our study, 105 of them were no biofilm developers, representing 63.75% of all the studied bacterium genera. We consider that standardization and quantification of biofilm development in Gram negative bacteria can be useful in clinical practice, because biofilm development ability can lead or focus the gold treatment of pathologies produced by these microorganisms.


Asunto(s)
Biopelículas/crecimiento & desarrollo , Bacterias Gramnegativas/crecimiento & desarrollo , Carga Bacteriana , Técnicas Bacteriológicas , Densitometría , Infecciones por Bacterias Gramnegativas/microbiología , Humanos , Estándares de Referencia , España , Especificidad de la Especie
11.
Rev. esp. quimioter ; 26(2): 97-102, jun. 2013. tab
Artículo en Español | IBECS | ID: ibc-113460

RESUMEN

El objetivo del estudio fue investigar la formación de biofilms en bacterias gramnegativas y cuantificar la producción de biofilm mediante la aplicación de una técnica que permitiese una comparación de los resultados de la formación de biofilm entre las diferentes especies de gramnegativos. Se estudiaron un total de 153 cepas de bacilos gramnegativos correspondientes a 12 especies bacterianas por el método de la densidad óptica aplicando una modificación de la técnica descrita por Stepanovic et al. Los valores obtenidos mediante el análisis de la densidad óptica permiten clasificar a los microorganismos en formadores fuertes, moderados, débiles y no formadores. Los resultados obtenidos se han expresado de dos maneras, ambas utilizando el mismo método estadístico: sin estandarizar, donde los controles fueron diferentes dependiendo de los días en los que se realizaron las medidas; y estandarizados mediante un factor de corrección, utilizando el mismo control para todas las cepas de cada especie, lo que permite su homogeneización. Los resultados obtenidos en el estudio tras el análisis y estandarización establecen que de las 153 cepas de gramnegativos estudiados, 105 de ellas fueron no formadoras de biofilms, representando el 63,75% de los géneros estudiados. Consideramos que la estandarización y cuantificación de la producción de biofilm entre las bacterias gramnegativas puede resultar de utilidad en el ámbito clínico, ya que el conocimiento de la capacidad de producción de biofilm puede dirigir o enfocar el tratamiento de elección de las patologías producidas por dichos microorganismos(AU)


The aim of the study was to investigate biofilm formation in Gram negative bacteria and to quantify biofilm production applying a new developed technique that made possible to compare results about biofilm formation within the different Gram negative bacteria species. A total of 153 Gram negative strains corresponding to 12 different bacterium species were studied applying a variation of the optic density measurement technique reported by Stepanovic et al. Data obtained with optic density analysis allow to classify microorganisms in strong biofilm developers, moderate biofilm developers, weak biofilm developers and no biofilm developers. The results were expressed in two ways, using in both cases the same statistical method: without standardization, where controls were different depending on the day optic density measurements were performed, and standardized using a correction factor, using the same control for every strain of all our bacterium species in our study, which allows result homogenization. The obtained results in our study after data analysis and standardization show that over the 153 Gram negative strains in our study, 105 of them were no biofilm developers, representing 63.75% of all the studied bacterium genera. We consider that standardization and quantification of biofilm development in Gram negative bacteria can be useful in clinical practice, because biofilm development ability can lead or focus the gold treatment of pathologies produced by these microorganisms(AU)


Asunto(s)
Humanos , Masculino , Femenino , Biopelículas/clasificación , Biopelículas , Bacilos y Cocos Aerobios Gramnegativos/aislamiento & purificación , Bacilos y Cocos Aerobios Gramnegativos/patogenicidad , Infecciones por Acinetobacter/microbiología , Acinetobacter baumannii/aislamiento & purificación , Pseudomonas aeruginosa/aislamiento & purificación , Stenotrophomonas maltophilia/aislamiento & purificación , Morganella morganii/aislamiento & purificación , Providencia/aislamiento & purificación , 51426 , Infecciones por Proteus/tratamiento farmacológico , Infecciones por Proteus/microbiología , Proteus mirabilis/aislamiento & purificación , Serratia marcescens/aislamiento & purificación , Citrobacter freundii/aislamiento & purificación , Salmonella enteritidis/aislamiento & purificación , Análisis Espectral/métodos
12.
J Antimicrob Chemother ; 68(10): 2291-5, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23674766

RESUMEN

OBJECTIVES: To explore serum and tissue pharmacodynamics of linezolid versus vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates with different MBC/MIC ratios. METHODS: Five strains (vancomycin MIC/MBCs, mg/L) were used: TOL-1 (2/≥64), TOL-2 (1/16), LT-1 and LT-2 (1/8) and NT (1/2). The linezolid MIC/MBC for all strains was 2/≥64 mg/L. A two-compartment dynamic computerized device was used (inocula 10(7) cfu/mL). Free concentrations obtained in serum and interstitial fluid with twice-daily regimens of 1 g of vancomycin or 600 mg of linezolid were simulated over 48 h. ABBCs (differences between control growth curves and killing curves of bacteria exposed to antibiotics; log10 cfu × h/mL) and log10 reductions in initial inocula were calculated. RESULTS: In serum simulations, vancomycin (AUC0-24/MIC = 251.8 for TOL-1 and 503.6 for the remaining strains) was bacteriostatic against strains with MBC/MIC ≥8, but bactericidal against NT. In interstitial fluid simulations (AUC0-24/MIC = 54.6 for TOL-1 and 109.2 for the remaining strains), initial inocula grew in all cases. Linezolid, both in serum (AUC0-24/MIC = 87.0) and in interstitial fluid (AUC0-24/MIC = 130.6) simulations, reduced initial inocula ≥2.2 log10 for all strains (apart from LT-1 in serum simulations that showed a bacteriostatic profile). ABBCs were similar in serum and interstitial fluid with linezolid, but significantly lower in interstitial fluid simulations with vancomycin. CONCLUSIONS: From the pharmacodynamic perspective (serum concentrations), vancomycin tolerance should include MBC/MIC ≥8 since strains exhibiting this ratio showed bacteriostatic profiles similar to those obtained with isolates with MBC/MIC ratios of 16 or 32. Insufficient concentrations of vancomycin at the simulated infected site were linked to bacteriological failure. Free concentrations of linezolid at the infection site pharmacodynamically covered MRSA.


Asunto(s)
Acetamidas/farmacología , Antibacterianos/farmacología , Líquido Extracelular/química , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Oxazolidinonas/farmacología , Suero/química , Vancomicina/farmacología , Acetamidas/farmacocinética , Antibacterianos/farmacocinética , Diabetes Mellitus , Humanos , Linezolid , Staphylococcus aureus Resistente a Meticilina/aislamiento & purificación , Pruebas de Sensibilidad Microbiana , Viabilidad Microbiana/efectos de los fármacos , Modelos Teóricos , Oxazolidinonas/farmacocinética , Vancomicina/farmacocinética
13.
Rev. esp. quimioter ; 25(4): 269-273, dic. 2012. ilus
Artículo en Español | IBECS | ID: ibc-108009

RESUMEN

Introducción. En la fibrosis quística las células de Pseudomonas aeruginosa crecen en el interior de la espesa mucosidad, y pese a ser un organismo aerobio estricto, se desarrolla en un ambiente donde la presión de oxígeno es muy limitada. Posibles movimientos de la masa mucosa podrían dejar expuestas de forma súbita a las células de P. aeruginosa a concentraciones altas de oxígeno. El objetivo del estudio fue determinar cómo afecta a la sensibilidad antibiótica de P. aeruginosa un período de incubación anaerobia. Material y métodos. Se emplearon 4 cepas de P. aeruginosa (NTCC 23389 y 3 aislados clínicos). Para la determinación de la sensibilidad antibiótica se empleó el método de difusión en agar. Resultados. La preincubación anaerobia produce cambios en la sensibilidad en todas las cepas estudiadas. Todas las cepas sensibles en aerobiosis resultaron también sensibles tras la incubación anaerobia a excepción de la cepa 2 para los betalactámicos. El tipo de respuesta resulta dependiente de cada cepa, siendo especialmente significativo el incremento en la sensibilidad observado en el caso de ciprofloxacino para dos de los tres aislados clínicos. Conclusiones. La sensibilidad de cepas P. aeruginosa varía si han sido previamente expuestas a condiciones de anaerobiosis. Tratamientos que favorezcan la fluidificación de la mucosidad podrían contribuir aumentando el éxito del tratamiento con ciertos antibióticos(AU)


Introduction. In cystic fibrosis, the Pseudomonas aeruginosa cells grow inside the thick mucus layer. In spite of being an obligate aerobe, P. aeruginosa is able to grow in a limited oxygen environment. Bacterial cells could be suddenly exposed to high oxygen levels due to the movements of the mucus mass. The aim of study was to determine the impact of a previous anaerobic incubation on the antimicrobial susceptibility of P. aeruginosa strains isolated from patients with cystic fibrosis. Materials and Methods. Four P. aeruginosa strains were used in this study (ATCC 23389 and 3 clinical isolates). The disk diffusion method was used to determine the antimicrobial susceptibility. Results. The anaerobic pre-incubation produced changes on the susceptibility in all studied strains. All susceptible strains after an aerobic incubation remained susceptible after an anaerobic incubation except one clinical strain, which became resistant to betalactams. The response was strain-dependent and the most significant increase in susceptibility was observed in two of the three clinical isolates when ciprofloxacin was used. Conclusions. The antimicrobial susceptibility of P. aeruginosa strains varies after their exposure to anaerobic conditions. Treatments promoting mucus fluidization could contribute to increase the antimicrobial efficacy(AU)


Asunto(s)
Humanos , Masculino , Femenino , /métodos , Agar/síntesis química , Agar/aislamiento & purificación , Pseudomonas aeruginosa , Pseudomonas aeruginosa/aislamiento & purificación , Fibrosis Quística/tratamiento farmacológico , Gentamicinas/uso terapéutico , Pruebas de Sensibilidad Microbiana/métodos , Sensibilidad y Especificidad , Aztreonam/uso terapéutico , Tobramicina/uso terapéutico , Dilución/métodos , Anaerobiosis
14.
PLoS One ; 7(9): e44135, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22957048

RESUMEN

BACKGROUND: Specific antibodies mediate humoral and cellular protection against invading pathogens such as Streptococcus pneumoniae by activating complement mediated immunity, promoting phagocytosis and stimulating bacterial clearance. The emergence of pneumococcal strains with high levels of antibiotic resistance is of great concern worldwide and a serious threat for public health. METHODOLOGY/PRINCIPAL FINDINGS: Flow cytometry was used to determine whether complement-mediated immunity against three antibiotic-resistant S. pneumoniae clinical isolates is enhanced in the presence of sub-inhibitory concentrations of cefditoren and ceftriaxone. The binding of acute phase proteins such as C-reactive protein and serum amyloid P component, and of complement component C1q, to pneumococci was enhanced in the presence of serum plus either of these antibiotics. Both antibiotics therefore trigger the activation of the classical complement pathway against S. pneumoniae. C3b deposition was also increased in the presence of specific anti-pneumococcal antibodies and sub-inhibitory concentrations of cefditoren and ceftriaxone confirming that the presence of these antibiotics enhances complement-mediated immunity to S. pneumoniae. CONCLUSIONS/SIGNIFICANCE: Using cefditoren and ceftriaxone to promote the binding of acute phase proteins and C1q to pneumococci, and to increase C3b deposition, when anti-pneumococcal antibodies are present, might help reduce the impact of antibiotic resistance in S. pneumoniae infections.


Asunto(s)
Antibacterianos/farmacología , Anticuerpos/química , Ceftriaxona/farmacología , Cefalosporinas/farmacología , Streptococcus pneumoniae/metabolismo , Proteínas de Fase Aguda/metabolismo , Animales , Activación de Complemento , Complemento C1q/química , Complemento C3c/química , Farmacorresistencia Microbiana , Ácido Egtácico/química , Citometría de Flujo/métodos , Humanos , Sistema Inmunológico , Ratones , Fagocitosis , beta-Lactamas/metabolismo
15.
PLoS One ; 7(8): e42393, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22879961

RESUMEN

This paper reports the effect of soda-lime-glass-nAg coating on the viability of an in vitro biofilm of Streptococcus oralis. Three strains (ATCC 35037 and two clinical isolates from periodontitis patients) were grown on coated with glass, glass containing silver nanoparticles, and uncoated titanium alloy disks. Two different methods were used to quantify biofilm formation abilities: crystal violet staining and determination of viable counts. The influence of the surface morphology on the cell attachment was studied. The surface morphology was characterized by scanning electron microscopy (SEM) and using a profilometer. SEM was also used to study the formation and the development of biofilm on the coated and uncoated disks. At least a >99.7% inocula reduction of biofilm respect to titanium disks and also to glass coated disks was observed in the glass-nAg coated disks for all the studied strains. A quantitative evaluation of the release of silver was conducted in vitro to test whether and to what extend the biocidal agent (silver) could leach from the coating. These findings suggest that the biofilm formation of S. oralis strains is highly inhibited by the glass-nAg and may be useful for materials which require durable antibacterial effect on their surfaces, as it is the case of dental implants.


Asunto(s)
Biopelículas/efectos de los fármacos , Compuestos de Calcio/farmacología , Vidrio/química , Nanopartículas del Metal/química , Óxidos/farmacología , Plata/farmacología , Hidróxido de Sodio/farmacología , Streptococcus oralis/fisiología , Titanio/farmacología , Aleaciones , Adhesión Bacteriana/efectos de los fármacos , Violeta de Genciana , Humanos , Nanopartículas del Metal/ultraestructura , Plancton/efectos de los fármacos , Coloración y Etiquetado , Streptococcus oralis/efectos de los fármacos , Streptococcus oralis/ultraestructura , Propiedades de Superficie , Temperatura
16.
Rev Esp Quimioter ; 25(1): 47-55, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22488542

RESUMEN

OBJECTIVES: the aims of the study were to explore the activity of total and free (according to protein binding) maximal concentrations achieved in serum after multiple doses of voriconazole 400/200 mg and anidulafungin 200/100 mg against Aspergillus fumigatus and Aspergillus flavus and the human albumin or serum effects on antifungal activity. MATERIAL AND METHODS: Time-kill curves were performed with two A. fumigatus and two A. flavus strains at voriconazole and anidulafungin Cmax concentrations using different media: a) RPMI broth (Cmax-RPMI); b) RPMI with human serum (Cmax-HS), and c) RPMI with human albumin (Cmax-HAlb). In parallel, free-drug (fCmax) concentrations considering theoretical protein binding were performed in RPMI broth. Aspergillus metabolic activity was measured by the XTT reduction assay. RESULTS: Voriconazol or voriconazole plus anidulafungin reduced >88.4% the metabolic activity of Aspergillus sp. at Cmax-RPMI and fCmax after 48 h of exposition. Anidulafungin alone showed poor metabolic reductions (<80.1% at Cmax- RPMI and <15% at fCmax). Anidulafungin activity, but not voriconazole activity alone or combined decreased in presence of HS or HAlb (more pronounced in A. flavus strains and HAlb). However, anidulafungin Cmax-HS or Cmax-HAlb against A. fumigatus strains were significantly more active (p<0.05) than fCmax in RPMI. These species and culture medium-dependent impact of human protein binding in the activity of anidulafungin was related to macroscopic and microscopic differences among mycelial mat grown in RPMI, HS or HAlb in whose XTT retention was different. CONCLUSIONS: Synergism could not be demonstrated due to the high activity showed by voriconazole. Protein binding has not impact on voriconazole activity and this impact is considerably less than predicted by free concentration extrapolated from theoretical binding rate on anidulafungin. The XTT colorimetric assay needs to be standardized for use with Aspergillus spp. since without DMSO extraction the activity of echinocandins in a free-human protein RPMI medium could be overestimated.


Asunto(s)
Antifúngicos/metabolismo , Antifúngicos/farmacología , Aspergillus/efectos de los fármacos , Equinocandinas/farmacología , Pirimidinas/metabolismo , Pirimidinas/farmacología , Triazoles/metabolismo , Triazoles/farmacología , Anidulafungina , Aspergillus/ultraestructura , Aspergillus flavus/efectos de los fármacos , Aspergillus flavus/ultraestructura , Aspergillus fumigatus/efectos de los fármacos , Aspergillus fumigatus/ultraestructura , Colorimetría , Medios de Cultivo , Combinación de Medicamentos , Humanos , Pruebas de Sensibilidad Microbiana , Unión Proteica , Albúmina Sérica/química , Sales de Tetrazolio , Factores de Tiempo , Voriconazol
17.
Rev. esp. quimioter ; 25(1): 47-55, mar. 2012. tab, ilus
Artículo en Inglés | IBECS | ID: ibc-99753

RESUMEN

Objetivos: los objetivos del estudio fueron valorar la actividad de las concentraciones máximas totales y libres (de acuerdo a la unión a proteínas) alcanzadas en suero después de dosis múltiples de voriconazol 400/200 mg y anidulafungina 200/100 mg frente Aspergillus fumigatus y Aspergillus flavus y el efecto del suero y albúmina humana en la actividad antifúngica. Material y métodos: las curvas de letalidad fueron realizadas con 2 cepas de A. fumigatus y 2 cepas de A. flavus a las concentraciones Cmax de voriconazol y anidulafungina empleando diferentes medios: a) caldo RPMI (Cmax-RPMI); b) RPMI con suero humano (Cmax-SH) y c) RPMI con albúmina humana (Cmax-AlbH). Se compararon con las concentraciones libres (fCmax) en caldo RPMI teniendo en cuenta la unión a proteínas. La actividad metabólica de las cepas de Aspergillus fue medida por la técnica de reducción de XTT. Resultados: voriconazol o voriconazol con anidulafungina redujeron la actividad metabólica de las cepas de Aspergillus >88.4% a las concentraciones Cmax-RPMI y fCmax después de 48 h de exposición. Anidulafungina sola mostró bajas reducciones metabólicas (<80.1% a Cmax-RPMI y <15% a fCmax). La actividad de anidulafungina, pero no la de voriconazol solo o combinado, disminuyó en presencia de suero o albúmina (más pronunciado para las cepas de A. flavus y con albúmina). Sin embargo, las concentraciones de anidulafungina Cmax-HS o Cmax-AlbH frente las cepas de A. fumigatus fueron significativamente más activas (p<0.05) que la concentración fCmax en RPMI. Este impacto de la unión a proteínas en la actividad de anidulafungina dependiente de la especie y el medio de cultivo fue relacionada con diferencias macroscópicas y microscópicas del crecimiento miceliar en RPMI, SH o AlbH en los cuales la retención fue diferente. Conclusiones: el sinergismo entre ambos antifúngicos no pudo ser demostrado probablemente por alta actividad mostrada por voriconazol. La unión a proteínas plasmáticas no tiene impacto en la actividad de voriconazol y su efecto es considerablemente menor sobre anidulafungina que el pronosticado por la concentración libre teórica extrapolada de la tasa de unión a proteínas. El método colorimétrico del XTT necesita ser estandarizado para ser empleado con Aspergillus sp. ya que sin la extracción con DMSO la actividad de las equinocandinas en el medio RPMI sin proteínas humanas podría ser sobreestimada(AU)


Objectives: the aims of the study were to explore the activity of total and free (according to protein binding) maximal concentrations achieved in serum after multiple doses of voriconazole 400/200 mg and anidulafungin 200/100 mg against Aspergillus fumigatus and Aspergillus flavus and the human albumin or serum effects on antifungal activity. Material and methods: Time-kill curves were performed with two A. fumigatus and two A. flavus strains at voriconazole and anidulafungin Cmax concentrations using different media: a) RPMI broth (Cmax-RPMI); b) RPMI with human serum (Cmax-HS), and c) RPMI with human albumin (Cmax- HAlb). In parallel, free-drug (fCmax) concentrations considering theoretical protein binding were performed in RPMI broth. Aspergillus metabolic activity was measured by the XTT reduction assay. Results: Voriconazol or voriconazole plus anidulafungin reduced >88.4% the metabolic activity of Aspergillus sp. at Cmax-RPMI and fCmax after 48 h of exposition. Anidulafungin alone showed poor metabolic reductions (<80.1% at Cmax- RPMI and <15% at fCmax). Anidulafungin activity, but not voriconazole activity alone or combined decreased in presence of HS or HAlb (more pronounced in A. flavus strains and HAlb). However, anidulafungin Cmax-HS or Cmax-HAlb against A. fumigatus strains were significantly more active (p<0.05) than fCmax in RPMI. These species and culture medium-dependent impact of human protein binding in the activity of anidulafungin was related to macroscopic and microscopic differences among mycelial mat grown in RPMI, HS or HAlb in whose XTT retention was different. Conclusions: Synergism could not be demonstrated due to the high activity showed by voriconazole. Protein binding has not impact on voriconazole activity and this impact is considerably less than predicted by free concentration extrapolated from theoretical binding rate on anidulafungin. The XTT colorimetric assay needs to be standardized for use with Aspergillus spp. since without DMSO extraction the activity of echinocandins in a free-human protein RPMI medium could be overestimated(AU)


Asunto(s)
Aspergillus , Aspergillus/aislamiento & purificación , Antifúngicos/análisis , Antifúngicos/uso terapéutico , Mortalidad , Antifúngicos/farmacología , Antifúngicos/farmacocinética , Aspergillus fumigatus , Aspergillus fumigatus/aislamiento & purificación , Análisis de Varianza
18.
Rev Esp Quimioter ; 25(4): 269-73, 2012 Dec.
Artículo en Español | MEDLINE | ID: mdl-23303259

RESUMEN

INTRODUCTION: In cystic fibrosis, the Pseudomonas aeruginosa cells grow inside the thick mucus layer. In spite of being an obligate aerobe, P. aeruginosa is able to grow in a limited oxygen environment. Bacterial cells could be suddenly exposed to high oxygen levels due to the movements of the mucus mass. The aim of study was to determine the impact of a previous anaerobic incubation on the antimicrobial susceptibility of P. aeruginosa strains isolated from patients with cystic fibrosis. MATERIALS AND METHODS: Four P. aeruginosa strains were used in this study (ATCC 23389 and 3 clinical isolates). The disk diffusion method was used to determine the antimicrobial susceptibility. RESULTS: The anaerobic pre-incubation produced changes on the susceptibility in all studied strains. All susceptible strains after an aerobic incubation remained susceptible after an anaerobic incubation except one clinical strain, which became resistant to betalactams. The response was strain-dependent and the most significant increase in susceptibility was observed in two of the three clinical isolates when ciprofloxacin was used. CONCLUSIONS: The antimicrobial susceptibility of P. aeruginosa strains varies after their exposure to anaerobic conditions. Treatments promoting mucus fluidization could contribute to increase the antimicrobial efficacy.


Asunto(s)
Fibrosis Quística/complicaciones , Pruebas Antimicrobianas de Difusión por Disco , Farmacorresistencia Bacteriana/fisiología , Infecciones por Pseudomonas/microbiología , Pseudomonas aeruginosa/efectos de los fármacos , Aerobiosis , Anaerobiosis , Antibacterianos/farmacología , Expectorantes/farmacología , Humanos , Viabilidad Microbiana , Moco/microbiología , Oxígeno/metabolismo , Infecciones por Pseudomonas/complicaciones , Pseudomonas aeruginosa/crecimiento & desarrollo , Pseudomonas aeruginosa/aislamiento & purificación , Pseudomonas aeruginosa/metabolismo , Sistema Respiratorio/microbiología
19.
Antimicrob Agents Chemother ; 55(6): 2788-94, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-21464255

RESUMEN

This study explores the effects of cefditoren (CDN) versus amoxicillin-clavulanic acid (AMC) on the evolution (within a single strain) of total and recombined populations derived from intrastrain ftsI gene diffusion in ß-lactamase-positive (BL⁺) and ß-lactamase-negative (BL⁻) Haemophilus influenzae. DNA from ß-lactamase-negative, ampicillin-resistant (BLNAR) isolates (DNA(BLNAR)) and from ß-lactamase-positive, amoxicillin-clavulanate-resistant (BLPACR) (DNA(BLPACR)) isolates was extracted and added to a 107-CFU/ml suspension of one BL⁺ strain (CDN MIC, 0.007 µg/ml; AMC MIC, 1 µg/ml) or one BL⁻ strain (CDN MIC, 0.015 µg/ml; AMC MIC, 0.5 µg/ml) in Haemophilus Test Medium (HTM). The mixture was incubated for 3 h and was then inoculated into a two-compartment computerized device simulating free concentrations of CDN (400 mg twice a day [b.i.d.]) or AMC (875 and 125 mg three times a day [t.i.d.]) in serum over 24 h. Controls were antibiotic-free simulations. Colony counts were performed; the total population and the recombined population were differentiated; and postsimulation MICs were determined. At time zero, the recombined population was 0.00095% of the total population. In controls, the BL⁻ and BL⁺ total populations and the BL⁻ recombined population increased (from ≈3 log10 to 4.5 to 5 log10), while the BL⁺ recombined population was maintained in simulations with DNA(BLPACR) and was decreased by ≈2 log10 with DNA(BLNAR). CDN was bactericidal (percentage of the dosing interval for which experimental antibiotic concentrations exceeded the MIC [ft>MIC], >88%), and no recombined populations were detected from 4 h on. AMC was bactericidal against BL⁻ strains (ft>MIC, 74.0%) in DNA(BLNAR) and DNA(BLPACR) simulations, with a small final recombined population (MIC, 4 µg/ml; ft>MIC, 30.7%) in DNA(BLPACR) simulations. When AMC was used against the BL⁺ strain (in DNA(BLNAR) or DNA(BLPACR) simulations), the bacterial load was reduced ≈2 log10 (ft>MIC, 44.3%), but 6.3% and 32% of the total population corresponded to a recombined population (MIC, 16 µg/ml; ft>MIC, 0%) in DNA(BLNAR) and DNA(BLPACR) simulations, respectively. AMC, but not CDN, unmasked BL⁺ recombined populations obtained by transformation. ft>MIC values higher than those classically considered for bacteriological response are needed to counter intrastrain ftsI gene diffusion by covering recombined populations.


Asunto(s)
Combinación Amoxicilina-Clavulanato de Potasio/farmacología , Antibacterianos/farmacología , Cefalosporinas/farmacología , Genes Bacterianos , Haemophilus influenzae/efectos de los fármacos , Combinación Amoxicilina-Clavulanato de Potasio/farmacocinética , Cefalosporinas/farmacocinética , Difusión , Farmacorresistencia Bacteriana , Haemophilus influenzae/genética , Humanos , Pruebas de Sensibilidad Microbiana , beta-Lactamasas/análisis
20.
Int J Antimicrob Agents ; 37(4): 332-8, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21388792

RESUMEN

In order to determine whether reduced susceptibility or tolerance to vancomycin in Staphylococcus aureus influences the activity of daptomycin by simulating serum concentrations in the first 24h of treatment in the presence of physiological concentrations of human albumin, a computerised pharmacodynamic simulation was performed using Mueller-Hinton broth with 4 g/dL human albumin concentrations. For daptomycin, the media was adjusted to physiological ionised calcium concentrations by adding 100 µg/mL Ca(2+). Protein binding was measured. Six S. aureus isolates were used, comprising one vancomycin-susceptible S. aureus (VSSA), three vancomycin-tolerant strains, one heteroresistant vancomycin-intermediate S. aureus (hVISA) and one homogeneous vancomycin-intermediate S. aureus (VISA). Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) of daptomycin increased eight times when determined in the presence of albumin (MIC(ALB) and MBC(ALB), respectively). Measured protein binding was 86.6% (C(max)) and 86.5% (C(min)) for daptomycin and 51.6% (C(max)) and 42.2% (C(min)) for vancomycin. Similar values were obtained for fAUC/MIC (where fAUC is the area under the concentration-time curve obtained with extrapolated concentrations using the highest protein binding rate experimentally obtained) and AUC/MIC(ALB) for each antibiotic. Daptomycin showed early (≤ 6 h) bactericidal activity [maximal effect (E(max)) >4 log(10) reductions in initial inocula] against all strains. Vancomycin produced an E(max) of 2.3 log(10) reductions at 8h against the VSSA and reductions ≤1.8 log(10) for the other strains in the 8-24h period. Pharmacodynamic parameters were fAUC/MBC from 8.0 to 15.6 (vancomycin) and from 56.0 to 111.6 (daptomycin) for tolerant strains, and fAUC/MIC of 126.8 and 63.3 for vancomycin and 222.6 and 113.2 for daptomycin against hVISA and VISA strains, respectively. Against the study strains (vancomycin-susceptible, -tolerant, heteroresistant or intermediate), daptomycin, in contrast to vancomycin, exhibited early bactericidal activity despite its high protein binding.


Asunto(s)
Antibacterianos/sangre , Daptomicina/sangre , Albúmina Sérica/fisiología , Staphylococcus aureus/efectos de los fármacos , Vancomicina/sangre , Antibacterianos/farmacocinética , Antibacterianos/farmacología , Área Bajo la Curva , Daptomicina/farmacocinética , Daptomicina/farmacología , Farmacorresistencia Microbiana , Pruebas de Sensibilidad Microbiana , Vancomicina/farmacocinética , Vancomicina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA